MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Cancer cachexia impacts almost 90% of people living with pancreatic cancer. Learn more about this condition in this Q&A with Nicolas Clifford, PanCAN’s manager of research and education communication.

A recent study identified disparities in cachexia incidence among patients with stage IV non–small cell lung cancer (NSCLC) across different racial, ethnic, and socioeconomic groups. An analysis of ...

Kalohexis, a newly created biotechnology company to advance the clinical development of a portfolio of drug candidates harnessing the melanocortin (MC) system for the treatment of metabolic disorders ...

A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they ...

A DGIST research team led by Professor Kyungmoo Yea of the Department of New Biology developed an antibody that effectively alleviates chemotherapy-induced cancer cachexia. The team's newly developed ...

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...

Cancer-associated cachexia is a multifactorial wasting disorder characterized by anorexia, unintentional weight loss (WL, skeletal muscle mass with or without loss of fat mass), progressive functional ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...